Compare MOMO & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOMO | CMPX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | China | United States |
| Employees | 1390 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 926.7M |
| IPO Year | 2014 | N/A |
| Metric | MOMO | CMPX |
|---|---|---|
| Price | $6.80 | $6.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $13.00 | ★ $13.44 |
| AVG Volume (30 Days) | 968.0K | ★ 2.6M |
| Earning Date | 03-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $1,464,746,462.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.12 | $1.33 |
| 52 Week High | $9.22 | $6.49 |
| Indicator | MOMO | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 61.54 |
| Support Level | $6.87 | $6.05 |
| Resistance Level | $7.02 | $6.49 |
| Average True Range (ATR) | 0.18 | 0.43 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 36.56 | 91.23 |
Hello Group Inc provides mobile-based social networking services. It enables users to establish and expand social relationships based on location and interests. Its platform includes the Momo mobile application and a variety of related features, functionalities, tools, and services that it provides to users, customers, and platform partners. The company derives its revenue from live video services, value-added services, mobile marketing services, mobile games, and other services. It operates in three segments: Momo's service lines, Tantan's service lines, and QOOL's service lines, out of which Momo's service lines segment derives the majority of revenue.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.